Background: Gln3 localization is hypothesized to be co-regulated by TorC1 and nitrogen limitation. Results: gln3 mutations abrogating Gln3-Tor1 interaction abolish the Gln3 response to rapamycin without adversely affecting its response to nitrogen limitation. Conclusions: Different Gln3 regions mediate responses to rapamycin and nitrogen limitation. Significance: Controlled Gln3 localization occurs via two separable regulatory pathways both of which are required for overall W.T. Gln3 control.
INTRODUCTION
The nitrogen catabolite repression-(NCR-) sensitive GATA transcription activator, Gln3, is one of the most often used reporters of TorC1 signaling activity in Saccharomyces cerevisiae. As such, its regulation has been investigated in substantial detail. The intracellular localization of Gln3 and another GATA-family transcription activator, Gat1, respond to both nitrogen limitation (NCR) and rapamycin treatment (TorC1-mediated regulation). The central question addressed in this work is whether NCR and rapamycin inhibitable, TorC1-mediated activity represent sequential steps of a single regulatory pathway or two independent regulatory mechanisms that work in concert to control the GATA family transcription factors.
When cells are cultured under nitrogen rich conditions, Gln3 and Gat1 are sequestered in the cytoplasm and transcription of the genes required to scavenge poor nitrogen sources is highly repressed (1) (2) (3) (4) (5) . Ure2, a preprion protein, is required for this cytoplasmic sequestration and repressed transcription (6) . The additional observation that Ure2 forms a complex with Gln3 in nitrogen rich conditions led to the conclusion that formation of this complex is a central step in nitrogen-responsive GATA factor regulation (6) (7) (8) (9) . In contrast, during nitrogen limitation, Gln3 is not complexed with Ure2 and relocates, along with Gat1, to the nucleus where they activate transcription of the nitrogen catabolic genes (7, 8, 10, 11) . This mechanism of regulation was long ago designated NCR (1) .
The fact that Gln3 and Gat1 also relocate to the nucleus following rapamycin treatment led to an elegant model concluding that their nitrogen-responsive, i.e., NCR-sensitive, regulation was achieved through nitrogen-responsive control of the TorC1 serine/threonine kinase complex and the PP2A-type phosphatases it regulates (7, 8, 10, 11) . In very gross outline, excess nitrogen was envisioned to activate TorC1 which in turn inhibited PP2A-type phosphatases. Loss of the phosphatase activities resulted in increased phosphorylation of Gln3 which complexed with Ure2. As a result of either phosphorylation or complexation with Ure2, Gln3 was unable to enter the nucleus and activate catabolic gene transcription. On the other hand, in limiting nitrogen, TorC1 was envisioned to be down-regulated, the PP2A-type phosphatases thereby activated, Gln3 dephosphorylated and dissociated from Ure2. Dephosphorylated Gln3 could then enter the nucleus and activate transcription. Consistent with this model: (i) rapamycin treatment results in Gln3 dephosphorylation, (ii) TorC1 pathway phosphatase, Sit4 is required for nuclear GATA factor localization in nitrogen-limited and rapamycin-treated cells (5, 7, 8, (12) (13) (14) (15) (16) (17) (18) (19) , and (iii) Tor1 has been shown to interact with the Cterminal region of Gln3 in a two-hybrid assay and to phosphorylate it in vitro (8, 12) .
However, more recent evidence contends that NCRsensitive and TorC1-dependent regulation of GATA factor localization and function may, in fact, be intersecting pathways of a larger network. Among the observations supporting this view: (i) Nitrogen limitation-induced nuclear GATA factor localization exhibits markedly different PP2A requirements than does rapamycin treatment (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . (ii) Demonstrable Gln3 phosphorylation/ dephosphorylation does not always correlate with its intracellular localization (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . Therefore, a major unresolved issue concerning the regulation of intracellular GATA factor localization is whether it unambiguously involves one mechanistic pathway or two. Stating the question in another way, is rapamycin-inhibited TorC1-mediated Gln3 regulation the means through which nitrogen-responsiveness (NCR) is exerted. One reason these questions remain somewhat open is that most existing work depends heavily upon inhibitors and mutations situated at various distances upstream of the Gln3 molecule whose localization is being measured, increasing the challenge of separating primary and secondary effects generated by the experimental perturbations. The problem is further exacerbated by the lability and complexity of the Gln3 molecule itself (20% of its residues are serine or threonine) which have largely frustrated direct mass-spectroscopic analyses of its phosphorylation (32) (33) (34) (35) .
Given the conceptual difficulty of cleanly separating primary and secondary responses of GATA factor localization to upstream perturbations, as well as the technical problems involved in biochemical approaches, we elected to take a systematic genetic approach to the question of Gln3 regulation. The rationale is predicated on the reasoning that if Gln3 localization and function involve multiple regulatory pathways, the individual pathways might possess distinct mutable and hence potentially identifiable targets within the Gln3 molecule itself. In the present work we report serine substitutions that diminish the ability of nitrogen replete growth conditions to sequester Gln3 in the cytoplasm. These substitutions completely abolish Gln3's response to rapamycin, but leave the NCR-sensitive response to limiting nitrogen untouched. We also show that Gln3 possesses at least one additional Tor1-interaction site beyond the one originally described.
MATERIALS AND METHODS
Strains and Culture Conditions -The Saccharomyces cerevisiae strain used as the transformation recipient in which gln3 mutant plasmids were assayed was JK9-3da (Table 1) . The protein interaction assays were performed in transformants of PJ69-4a (Table 1) . Growth conditions were identical to those described in Tate et al. (28) . Cultures (50 ml) were grown to mid-log phase (A 600 nm = 0.5) in YNB (without amino acids or ammonia) minimal medium containing the indicated nitrogen source at a final concentration of 0.1%. Appropriate supplements (120 g/ml leucine, 20 g/ml histidine and tryptophan) were added to the medium as necessary to cover auxotrophic requirements. Where indicated, cells were treated with 200 ngm/ml rapamycin for 20 mins. or 2 mM Msx for 30 mins. as described earlier.
Plasmid Construction and Protein-Protein Interaction Assays -gln3 deletion and amino acid substitution mutants were constructed using standard PCR based methods and the primer sets in Table 2 . The Myc 13 and ADH1 transcriptional terminator were derived from pKA62 (36) . The template for all of the constructions was pRR536 which contained the wild type GLN3 gene, including its native promoter, fused in frame with Myc 13 at the GLN3 translational stop codon.
PCR fragments using pRR536, pRR614 and pRR850 as template were generated and cloned into interaction vectors pACT-2 (Clonetech Inc.) to yield GAL4p(AD)-gln3 fusion plasmids, pRR1065, pRR1067 and pRR1069, respectively. Two plasmids (pRR1098 and ppRR1101), containing the 17 amino acid sequence the of Gln3 654-670 peptide, were constructed by cloning synthetic double stranded olignonucleotides into the pACT-2 vector. All of the constructs were confirmed by DNA sequencing (University of Tennessee Health Science Center Molecular Resource Center DNA sequencing facility).
GAL4-BD pASTOR(1-2470) and pASTOR1 (1-1760) were generously provided by Professor Stephen Zheng (12) . Positive control plasmids pTD1-1 (SV40 Large T antigen) and pLAM5 (human laminC) were obtained from Clonetech. The Gal4p-BD and AD fusion proteins were expressed together in yeast strain PJ69-4a. This strain was constructed in the W303 genetic background. We used it for our Tor1 interaction assays rather than a JK9-3da-derived strain so that Tor1-association data obtained in the present work could be directly compared with that from Carvalho et al. (12) .
The protein-protein interaction assays we used were those generously provided by Carvalho et al. and measured growth of PJ69-4a transformants on synthetic complete medium (SC) lacking leucine, tryptophan, and adenine as the positive control or synthetic complete medium lacking leucine, tryptophan, and histidine plus 3 mM (final concentration) 3-amino-1,2,4-triazole (3-AT) to assess whether or not a positive interaction occurred.
Western Blot Analyses -Western blot analyses were performed using a combination of methods described earlier (22, 28, 29, 37) . The antibodies used to visualize Gln3-Myc 13 , were primary monoclonal antibody 9E10 (c-myc) (Covance MMS-150P) and secondary goat antimouse IgG (H-L)-horseradish peroxidase conjugate (BioRad). Western blot results were recorded on Kodak BioMax XAR film. A wide range of exposures were collected for each sample and brightness settings of the final images uniformly changed to insure that no minor bands were lost and that the final images reproduced the actual x-ray films as closely as possible.
Indirect Immunofluorescence Microscopy -Cell collection and immunofluorescent staining were performed as previously described (21, 23, 26, 28) . Cells were fixed by addition of 0.55 ml of 1 M potassium phosphate buffer (pH 6.5) and 0.5 ml of 37% formalin to a 5 ml aliquot of the culture to be assayed. This was followed by incubation for 80 mins. at 30 o C. Gln3-Myc 13 was visualized using 9E10 (c-myc) (Covance MMS-150P) monoclonal antibody and Alexa Fluor 594 goat anti-mouse IgG (Invitrogen Molecular Probes) antibodies. DNA was stained with DAPI. Cells were imaged using a Zeiss Axioplan 2 imaging microscope with a 100x PlanApochromat 1.40 oil objective at room temperature. Images were acquired using a Zeiss Axio camera and AxioVision 3.0 and 4.8.1 (Zeiss) software, and processed with Adobe Photoshop and Illustrator programs.
Level settings (shadow and highlight only) were altered where necessary to avoid any change or loss in cellular detail relative to what was observed in the microscope; changes were applied uniformly to the image presented and were similar from one image to another.
Determination of Intracellular Gln3-Myc 13 Distribution -It is impossible to obtain a quantitative estimate of Gln3-Myc 13 localization viewing a single image containing 4-10 cells unless Gln3 is overwhelmingly in a single cellular compartment. This is due to both uneven distributions of cells exhibiting mixed Gln3 localizations (e.g., cytoplasmic and nuclear-cytoplasmic) and subjectivity in image selections. Therefore, we quantitated intracellular Gln3-Myc 13 localization by manually scoring Gln3-Myc 13 localization in 200 or more cells in multiple, randomly chosen fields from which each image presented was taken. Scoring was performed exclusively using unaltered, primary .zvi image files viewed with Zeiss AxioVision 3.0 and 4.8.1 software.
Cells were classified into one of three categories: cytoplasmic (cytoplasmic Gln3-Myc 13 fluorescence only; red bars), nuclear-cytoplasmic (Gln3-Myc 13 fluorescence appearing in the cytoplasm as well as co-localizing with DAPI-positive material; yellow bars), and nuclear (Gln3-Myc 13 fluorescence co-localizing only with DAPIpositive material; green bars). A representative collection of "standard" images demonstrating the differences in these categories is shown in Fig. 2 of ref. 28 along with a description of how the criteria were applied. Following recent recommendations (38) we assessed the precision of our scoring by analyzing the data from 10 different experiments performed over a nine month period; all appear in this work. The average values and standard deviations observed for the five conditions we assayed appear in Fig. 1 . These data add additional support to previous measurements by Tate et al. (23, 25, 29) . Similar experiments were repeated two or more times with similar results. Images accompanying the histograms were selected on the basis that they exhibited intracellular Gln3-Myc 13 distributions as close as possible to those observed in the quantitative scoring data.
RESULTS

Use of Gln3 Structural Mutants to Dissect Gln3
Regulation -To investigate the individual contributions of TorC1 and NCR to the regulation of Gln3 localization, we decided to use the Gln3 molecule itself not only as a reporter but also as a more direct probe to separate these regulatory pathways. However, the intractability of Gln3 to mass spectral analysis of its phosphorylation (32) (33) (34) (35) , prompted an alternative genetic approach to pursue this objective. The magnitude of the overall task -Gln3 contains 146 potentially phosphorylated serine/threonine residues -made it untenable to study the entire molecule by guest on September 16, 2017 http://www.jbc.org/ Downloaded from at once. Therefore, we have first focused on its Cterminal region. This is the region reported to be associated with Tor1 and the one about which the least is known. It also possesses the additional asset of being distanced from known Gln3 basic functional domains, i.e., nuclear import and export, DNA binding, transcriptional activation and Ure2 interaction, situated in the Nterminal portion of the protein (8, 12, 19) .
Before such genetic analyses could be confidently pursued, three important technical issues required evaluation. Taking full advantage of Gln3 amino acid substitution mutant proteins now and in the future required the capability of expeditiously introducing them into multiple wild type, TorC1 pathway and other mutant strains. This goal is most efficiently accomplished using Cenplasmid-borne constructs. Even though Cen-based expression systems are relatively stable and the Myc 13 tag has been repeatedly shown not to adversely affect Gln3 function, two pertinent questions remained: (i) would plasmid-borne mutants in which GLN3 was expressed from its own promoter, yield sufficiently reproducible data to be useful? (ii) Would the results obtained be the same as when GLN3 was situated in its native chromosomal location? To address these questions, we constructed a Cen-plasmid-borne wild type GLN3 gene driven by its native promoter (pRR536) and surveyed the range of conditions that regulate Gln3 localization: (1) highly repressive, nitrogen replete conditions (glutamine-grown) where Gln3 1-730 -Myc 13 is completely cytoplasmic, (2) derepressive, nitrogen-limited conditions (proline-grown) where it is completely nuclear and (3) following rapamycin treatment in nitrogen-rich media where it is localized to both cellular compartments.
First, we assessed our assay's reproducibility. Data depicted in Fig. 1A represent the averaged results of ten experiments performed over a nine month period, measuring Gln3 1-730 -Myc 13 localization in wild type JK9-3da transformed with wild type Gln3 1-730 -Myc 13 pRR536. The maximum standard deviation observed with these data was +/-~7-8%. It is important to note that the most challenging conditions to assay are those in which Gln3 1-730 -Myc 13 localizes to all three scoring categories, i.e., cytoplasmic, nuclear-cytoplasmic and nuclear. These data supported the contention that our plasmid-based assays exhibited sufficient precision to be useful.
Second, we queried whether the plasmid-borne Gln3 1-730 -Myc 13 reporter (pRR536) yielded results similar to those obtained with a strain in which Gln3-Myc 13 was situated at its native chromosomal position (TB123). Fig. 1B depicts data from four experiments performed over three years with TB123. Note that TB123 was derived from and is nearly isogenic to JK9-3da ( Table 1 ). The only difference noted in data obtained by the two methods was a small but consistent nuclear shift of plasmid-derived Gln3 1-730 -Myc 13 compared to that from chromosomal Gln3 1-730 -Myc 13 (Fig. 1A, pRR536 and Fig. 1B, TB123) .
The final technical issue was the nature of the transformation recipient. Two choices existed, wild type cells containing an unaltered chromosomal GLN3 allele in addition to the plasmid borne gln3-Myc 13 mutant allele or a gln3 in which the plasmid-borne gln3-Myc 13 mutant allele was the only one present in the cell. From extensive previous experience, we were well aware that diminishment or loss of Gln3 activity has far reaching secondary effects on many cellular processes. Moreover, there is no evidence that we know of demonstrating that regulation of Gln3 function is exerted through the amount of Gln3 produced unless it is ectopically overproduced at very high levels (39; Cooper et al., unpublished observations). This derives from the fact that Ure2, the titratable negative regulator of Gln3 and Gat1 (9), is present in the cell at much higher concentrations than Gln3. Given this information, we decided it was most prudent to use a wild type GLN3 strain (JK9-3da) as the transformation recipient, thereby divorcing potential secondary effects caused by Gln3 deficiency in some mutants but not others from primary effects on its localization. Comparison of data in Fig. 1A and B support the validity of this decision. Together, the results demonstrated that we could confidently make meaningful measurements of Gln3-Myc 13 localization in this new genetic context.
Analysis of the Gln3 Region Reported
To Bind Tor1 -In well performed experiments, Carvalho et al. reported that Gln3 510-730 -Myc 9 and Gln3 600-730 -Myc 9 peptides were sufficient to support association with Tor1 in a twohybrid interaction assay, whereas a Gln3 667-730 -Myc 9 peptide was not (8, 12) . Micrographic data positively correlated with the 2-hybrid results (12) . Together these data led to the conclusion that Tor1 kinase interacted with the Gln3 600-667 -Myc 9 region and was responsible for nitrogen-responsive Gln3 regulation. However, we noted that the reported localization results were qualitative being derived from overall evaluation of isolated micrographs in which Gln3-Myc 9 was concluded to be either nuclear or cytoplasmic. Such qualitative evaluation would have limited or abrogated any ability to detect intermediate changes in Gln3-Myc 9 localization if they occurred. These limitations prompted us to reevaluate the extent to which Tor1 could account for the totality of nitrogenresponsive Gln3 regulation. If inactivation of Tor1, either as a result of nitrogen limitation or rapamycinmediated inhibition, was the sole determinant responsible for nitrogen-responsive Gln3 regulation, then elimination of or specific substitutions in Gln3 residues 600-667 should result in highly nuclear Gln3 localization similar to levels that we and others have reported in by guest on September 16, 2017 http://www.jbc.org/ Downloaded from derepressed, proline-grown cells. If, on the other hand, control of nitrogen-responsive Gln3 localization derived from the combined effects of two mechanistic pathways acting together, then truncation of or amino acid substitutions in Gln3 might be expected to damage one of these regulatory mechanisms, but not the other.
We initially tested the above predictions rather crudely by sequentially truncating the C-terminus of Gln3. We included in our analyses a construct, Gln3 1-600 -Myc 13 (pRR614), analogous to one previously characterized by Carvalho et al.; we considered it to be a negative control (12) . The data we obtained were both intriguing and provocative. From Carvalho et al.'s data, we expected Gln3 to become exclusively nuclear in wild type cells containing the truncated, glutamine-grown negative control (Gln 1-600 -Myc 13 ). This didn't occur. Although Gln3 1-600 -Myc 13 was more nuclear than wild type Gln , thus supporting Carvalho et al.'s qualitative observation, a substantial amount of it, roughly 2/3 to 3/4 remained either cytoplasmic or nuclear-cytoplasmic when glutamine was provided as sole nitrogen source ( Fig. 2A  and 2B ). Even when Gln3 was more drastically truncated to residues 584 (pRR622), 565 (pRR621) and 542 (pRR613), no further nuclear Gln3-Myc 13 localization occurred ( Fig. 2A and 2B) . In other words, these truncations were insufficient to relocate Gln3-Myc 13 completely into the nucleus, thus arguing that at least two regulatory mechanisms were required to account for total control of Gln3 localization.
This conclusion was further supported when the data were viewed from the opposite perspective. The localizations of Gln3 1-600 -Myc 13 , Gln3 1-584 -Myc 13 , and Gln3 1-542 -Myc 13 were much less cytoplasmic than observed for glutaine-grown, full length Gln3 1-730 -Myc 13 ( Fig. 2A and  2B ). This indicated that although Gln3 600-730 materially contributed to sequestering Gln3-Myc 13 in the cytoplasm, these residues and their reported Tor1 interaction could account for only a portion of the cytoplasmic Gln3-Myc 13 sequestration observed with Gln3 1-730 -Myc 13 .
We observed a second, equally important characteristic of the Gln3 1-600 -Myc 13 , Gln3 1-584 -Myc 13 and Gln3 1-542 -Myc 13 truncations. Treating them with rapamycin failed to further increase their nuclear localization. In all cases, the ratio of cytoplasmic Gln3-Myc 13 in the presence vs. absence of rapamycin decreased from 3:1 in wild type to 1:1 in all of the mutants (Fig. 2C) . We also noted that the overall intracellular distributions of the Gln3 1-600 -Myc 13 , Gln3 1-584 -Myc 13 and Gln3 1-542 -Myc 13 truncations in the presence or absence of rapamycin were the same as that seen with full length Gln3 1-730 -Myc 13 in wild type glutamine-grown, rapamycin-treated cells (Fig. 2 B) .
From both perspectives, the above observations suggested that high level cytoplasmic sequestration of wild type Gln3-Myc 13 likely derived from two regulatory mechanisms. One depended on Gln3 residues 600-730, which were also responsible for the rapamycinresponsiveness of Gln3-Myc 13 localization. The second mechanism was not rapamycin-responsive and remained unaffected even when Gln3 was truncated by as much as ~25%.
We hypothesized that if this second mechanism derived from NCR, then the cytoplasmic Gln3-Myc 13 sequestration observed with the truncated forms of Gln3-Myc 13 in Fig. 2 should continue to be nitrogenresponsive, i.e., when cells were provided with a derepressive nitrogen source (proline), the cytoplasmic and nuclear-cytoplasmic Gln3-Myc 13 should relocate into the nucleus. We tested this expectation by comparing localization of the truncated versions of Gln3-Myc 13 in repressive vs. derepressive conditions, i.e., glutaminevs. proline-grown cells (Fig. 3A and 3B ). All four Gln3 truncations exhibited wild type NCR-sensitive responses. Derepressive growth conditions, using proline as sole nitrogen source, resulted in nearly complete nuclear Gln3 1-600 -Myc 13 , Gln3 1-584 -Myc 13 , Gln3 1-565 -Myc 13 and Gln3 1-542 -Myc 13 localizations. These observations supported the existence of a second regulatory mechanism and additionally demonstrated that the Gln3 target for it was N-terminal of Gln3 542 .
Identification of Gln3 Residues Required for the Rapamycin Response -Although the above truncations dissected rapamycin-inhibitable, Tor1 associationdependent responses of Gln3-Myc 13 localization away from responses that were NCR-sensitive, they represented rather blunt analytical probes. Removing up to ¼ of the Gln3 protein (130-188 residues) would not permit us to rigorously conclude that both diminished cytoplasmic sequestration of Gln3-Myc 13 in nitrogen-replete conditions and the loss of rapamycin-responsiveness derived solely from the loss of a Tor1-association site; much higher resolution was necessary.
Using systematic amino acid substitutions, we achieved the desired degree of resolution and addressed whether substituting non-phosphorylatable or phosphomimetic alanine or asparate residues, respectively, for serine/threonine residues in the C-terminal region of Gln3 affected its localization or the ability of TorC1 and/or rapamycin treatment to influence it. We sequentially replaced small groups of serine/threonine residues in the Gln3 600-667 region that Carvalho et al. reported to contain a Tor1-binding domain (Fig. 4A) (12) . All of our substitutions were situated in full length Gln3 proteins whose production was regulated by the native GLN3 promoter. We reasoned that: (i) substituting phosphomimetic aspartate for serine/threonine residues directly participating in TorC1 control of Gln3 would 13 constitutively into the nucleus, and (iii) in instances where Gln3 structure per se, rather than specific phosphorylation, was altered by the substitutions, the aspartate and alanine substitutions would generate similar results.
The first cluster of substitutions, Gln3 S603D , T605D , T607D , S609D -Myc 13 (pRR1014) had little demonstrable effect on Gln3-Myc 13 localization either in the presence or absence of rapamycin (Fig. 4B and 4C , compare wild type Gln3 1-730 -Myc 13 (pRR536) with Gln3 S603D , T605D , T607D , S609D -Myc 13 (pRR1014), Gln vs. Gln +Rap). Further, the NCR-sensitive response was similarly unaffected ( Fig. 4B and 4C , compare wild type and mutant responses to glutamine (Gln) vs. proline (Pro)). We next assayed Gln3 localization in Gln3 S616D , S617D , S619D, S621D, S624D, S631D -Myc 13 (pRR922) and Gln3 S616A , S617A , S619A, S621A, S624A, S631A -Myc 13 (pRR960) (Fig. 5) . Again, there was virtually no change from the wild type phenotypes (Fig. 5) . Moving further towards the C-terminus, we then assayed Gln3 T641D, S645D, S647D, S649D, S652D , S653D (pRR928) and Gln3 T641A, S645A, S647A, S649A, S652A , S653A -Myc 13 (pRR966) and yet again -there was no change from the wild type phenotype (Fig. 6 ). This was remarkable. Substituting aspartate for 25% or 16 of 53 residues, four to six at a time, and thereby substantially increasing the region's acidity yielded no demonstrable phenotype.
Finally, we assayed Gln3 S656D, S659D, S662D -Myc
13
(pRR850) and Gln3 S656A, S659A, S662A -Myc 13 (pRR1038) (Fig. 7) . The response was crystal clear; the phenotypes of both the aspartate (Gln3 S656D, S659D, S662D , pRR850) and alanine (Gln3 S656A, S659A, S662A , pRR1038) substitutions were indistinguishable. They mirrored the phenotype of the original Gln3 1-600 -Myc 13 truncation (Compare Figs. 2 and 3 with Fig. 7) . Cytoplasmic Gln3-Myc 13 localization decreased from over 90% in the wild type Gln3 1-730 -Myc 13 pRR536 to 30-40% in the mutants. Rapamycin treatment was without effect, yet the NCR response was wild type in Gln3 S656D, S659D, S662D (pRR850) and Gln3 S656A, S659A, S662A (pRR1038), i.e., Gln3-Myc 13 shifted completely into the nuclei of proline-grown cells (Fig.  7) .
In sum, only the very end of Gln3 600-667 was required and, within the resolution we could measure, accounted for all of the phenotypic characteristics observed in our Gln3 1-600 -Myc (pRR1038) exhibited the same intracellular distribution profiles indicated that the effects most likely derived from an alteration of the Gln3 656-662 structure itself rather than from specific phosphorylation or dephosphorylation of the substituted residues acting as the direct determinant of Gln3 localization. It was additionally significant that one could dramatically increase the acidity of Gln3 over a 50 residue region without effect on its regulated localization. Retain an Absolute Ure2 Requirement -Substitution of just three serine residues appeared to dissect the contribution of rapamycin-inhibited, i.e., TorC1-dependent regulation of Gln3-Myc 13 localization away from that imposed by NCR. If the Tor1-independent, second regulatory mechanism controlling Gln3 localization was truly NCR, then the cytoplasmic sequestration of the Gln3 truncation and Gln3 S656, S659, S662 substitution mutants should be Ure2-dependent. As noted earlier, Ure2 had long been known to: (i) be a negative regulator of Gln3 function (1-5), (ii) form a Gln3-Ure2 complex (6-9) and (iii) be required to maintain cytoplasmic Gln3 localization in nitrogen-replete medium (6-9). To test this expectation, CEN-plasmids expressing Gln3 1-730 -Myc 13 (pRR536), Gln3 1-600 -Myc 13 (pRR614) and Gln3 S656D, S659D, S662D -Myc 13 (pRR850) were transformed into ure2 RR215 and Gln3-Myc 13 localization assayed. The loss of Ure2 resulted in complete nuclear localization of Gln3-Myc 13 carried in all three plasmids transformed into glutamine-grown cells (Fig. 8) . Thus, not only was the second Gln3 regulatory mechanism nitrogen source responsive, it also exhibited an absolute requirement for Ure2, both hallmarks of NCR-sensitive control.
Cytoplasmic Sequestration of Gln3-Myc 13 in Strains Altered in Gln3
Changes 13 Phosphorylation -Treating glutamine-or YPD-grown wild type cells with rapamycin results not only in nuclear Gln3 localization, but also in gross Gln3 dephosphorylation thereby increasing its migration rate in SDS-PAGE gels (7, 8, 22) . This was one of the foundational correlations from which the earliest model for Tor1-mediated Gln3 regulation derived (7). Therefore, the inability of Gln3 1-600 -Myc 13 (pRR614), Gln3 S656D, S659D, S662D -Myc 13 (pRR850) and Gln3 S656A, S659A, S662A -Myc 13 (pRR1038) to relocate to the nucleus following rapamycin addition prompted us to determine whether or not rapamycin-elicited Gln3 dephosphorylation was also lost in these mutants. If gross Gln3 dephosphorylation is a determinant of its localization, then the two processes should respond in parallel to alterations in Gln3.
As expected, full length wild type Gln3 1-730 -Myc 13 (pRR536) exhibited strong dephosphoryation following addition of rapamycin (Fig. 9) . The normal slower migrating Gln3 1-730 -Myc 13 species chacteristic of hyperphosphorylated Gln3 (upper black dot between lanes 1 and 2) was minimally detectable in the rapamycinby guest on September 16, 2017 http://www.jbc.org/ Downloaded from treated cells, whereas the lower, hypo-phosphorylated Gln3 1-730 -Myc 13 (pRR536) species (lower black dot between lanes 1 and 2) was prominent. In contrast, rapamycin elicited a smaller difference in Gln3 1-600 -Myc 13 (pRR614) phosphorylation levels. In the untreated culture, the hyper-phosphorylated species (pRR614, upper black dot between lanes 1 and 2) predominated with little evidence of a clear band corresponding to the hypophosphorylated species (lower black dot). In Gln3 1-600 -Myc 13 rapamycin-treated cells, both hyper-and hypophosphorylated forms appear. Although the hyperphosphorylated species still predominated, the hypophosphorylated species was now clearly present and in greater abundance than observed in the untreated cells. Thus rapamycin-elicited Gln3 dephosphorylation had been damaged but not destroyed in the truncation mutant.
When a more focused alteration was made in Gln3, the resulting protein, Gln3 S656D, S659D, S662D -Myc 13 (pRR850), exhibited a phosphorylation profile with even greater similarity to that of the wild type Gln3 1-740 -Myc 13 (pRR536) than did Gln3 1-600 -Myc 13 (pRR614). The more slowly migrating species dominated in untreated cells, whereas the more rapidly migrating species dominated following rapamycin addition. The same predominance of the faster migrating species was also observed with rapamycin-treated Gln3 S656A, S659A, S662A -Myc 13 (pRR1038). The more slowly migrating species also predominated in untreated cells. Together, these data indicated that Gln3 sequences 600-730 were substantially, though not absolutely, required for high-level, rapamycin-elicited Gln3 dephosphorylation and that within this region, Gln3 residues 656, 659, and 662 did not play a particularly important role. Therefore, Gln3 S656D, S659D, S662D -Myc 13 and Gln3 S656A, S659A, S662A -Myc 13 dephosphorylation and localization did not parallel one another in rapamycin-treated cells. These data also further demonstrated that rapamycin-elicited gross dephosphorylation of Gln3 is not sufficient to cause its relocation into the nucleus.
Decreased cytoplasmic Gln3-Myc 13 We tested this prediction with the two-hybrid assay system used and generously provided by Carvalho et al. (12) . First, we confirmed, that the assay system behaved the same in our hands as in the Zheng laboratory; growth in the presence of 3-aminotriazole (3AT) signified positive in vivo protein-protein interaction. The positive (Fig.  10A , panels B and E, minus and plus 3AT, respectively), negative (panels A and D), and empty vector (panels C and F) controls all behaved as expected. Confident in the assay, we transformed each of three Gln3 "prey" plasmid constructs [(i) wild type Gln3 (pRR1065), (ii) Gln3 1-600 (pRR1067) or (iii) Gln3 S656D, S659D, S662D (pRR1069)] into a strain containing either pASTOR1-2470 (full length Tor1 1-2470 , panels M-O) or pASTOR1-1764 (truncated Tor1 , panels G to L) as the bait plasmid (Fig. 10B) (12) . The three "prey" plasmids contained wild type and mutant gln3 genes identical to those in pRR536, pRR614 and pRR850, respectively, except for elimination of the Myc 13 tag. We then assayed 36 independent transformants for each pair of plasmids in the absence (panels G-I) or presence (panels J-O) of 3AT. Only pASTOR1-1764 transformants grown in the absence of 3AT, the positive control for cells containing both plasmids, are shown in the figure (panels G-I); analogous pTOR1-2470 transformants yielded similar data (data not shown).
To our great surprise, all three bait plasmids supported growth in the presence of 3AT, indicating positive associations with full length Tor1 (Fig. 10B , panels M-O). ' s earlier results, we minimally expected Gln3 1-600 (pRR1067) to be incapable of associating with Tor1 and hence had included it as a negative control for our two-hybrid assays. But that was not the case.
The exceptional nature of the above results prompted us to repeat the two-hybrid assays using a Tor1 truncation containing the HEAT repeats reported to interact with Gln3 as the two-hybrid "bait" plasmid (pASTOR1-1764) (8) . Results identical to those observed with "bait" plasmid pASTOR1-2470 were obtained, i.e., all three types of transformants grew in the presence (Fig. 10B , panels J-L) and absence (panels G-I) of 3AT.
A Short, Potential -helix Interacts with Tor1 -The striking incongruities between our results and those reported by Carvalho et al. required explanation. We reasoned the differences might have conceivably derived from: (i) technical defects in our assays, or (ii) a fundamental, but unrecognized difference between the previous and present experimental strategies. Indeed, the latter explanation turned out to be the source of the dispari-
that Tor1-interacted with the Gln3 600-667 peptide. The key feature of their strategy was the use of isolated Gln3 peptides lacking Gln3 sequences N-terminal of residues 510, 600 and 667, respectively. We, on the other hand, employed C-terminal truncations, Gln3 1-600, and the Gln3 S656, S659, S662 substitutions in full length Gln3 molecules. In other words, all of our constructions contained all residues N-terminal to Gln3 600 . Therefore, if Gln3 contained more than one Tor1 interacting site Nterminal of Gln3 600 , it would have been missed in Carvalho et al.'s experiments which accounts for the lack of congruency between our data and theirs.
Our functional assays had already demonstrated that minimally, Gln3 residues 656-662 were required for full cytoplasmic sequestration of Gln3-Myc 13 and that those in Gln3 600-653 were not (Figs. 5-8 ). Therefore, we focused our attention on a 17 amino acid Gln3 654-670 peptide that contained Gln3 656-666, a sequence predicted by the Psipred secondary structure prediction method to potentially fold into an -helix ( Fig. 4A and 11B) (40, 41) . Further, the substituted serine residues in Gln3 S656D, S659D, S662D -Myc 13 (pRR850) were all situated on the same face of this putative Gln3 654-670 -helix peptide, if it existed in this form (Fig. 11 , substituted serine residues appear as white letters). We reasoned, based on these results, that the Gln3 654-670 peptide potentially contained the Tor1 interacting site situated in the C-terminal region of Gln3. This in turn predicted that the wild type Gln3 654-670 peptide (pRR1098) would interact with Tor1, whereas this peptide containing aspartate or alanine substitutions [Gln3 S656D, S659D, S662D (pRR1101); Gln3 S656A, S659A, S662A (pRR1160)] would not. These predictions were validated experimentally. The wild type Gln3 654-670 peptide interacted with Tor1 (Fig. 12B , images M and Q), whereas the mutant peptides did not (Fig. 12B , images N and R). Note that wild type Gln3 1-730 and Gln3 S656D, S659D, S662D (pRR1065 and pRR1069, respectively) again both yielded positive interactions with Tor1 (Fig. 12B , images G and H in the absence and panels K and L and O and P in the presence of 3AT). Fig. 12A , panels A-F depict the 2-hybrid assay controls, all of which yielded the expected results. Finally, we noted that when the entire set of independent replicate transformants, containing either wild type or mutant forms of the Gln3 654-670 peptide, were viewed as a whole, it appeared that the alanine substitutions exhibited a slightly greater interaction with Tor1 1-2470 (growth on +3AT) than the aspartate substitutions. Together, these data indicated that Gln3 possessed at least two sites that were able to associate, directly or indirectly, with Tor1 and that one of them was situated between Gln3 residues 654 and 670.
DISCUSSION
Parsing Tor1-and NCR-Associated Regulation of Gln3 Localization -Experiments interrogating the Cterminal region of Gln3 have genetically separated TorC1-and NCR-associated regulation of Gln3 localization. Specifically, elimination of / or amino acid substitutions in a 11 amino acid peptide with a theoretical potential to fold into an -helix, Gln3 656-666 , abolished the ability of: (i) Gln3 to associate with Tor1 in a two-hybrid assay, (ii) nitrogen rich conditions to completely sequester Gln3 in the cytoplasm, and (iii) rapamycin to elicit increased nuclear Gln3 localization in glutaminegrown cells. The Tor1-Gln3 association requirement for complete cytoplasmic sequestration is consistent with a requirement of the Tor1 kinase activity to achieve this end. This interpretation is consistent with Carvalho et al.'s in vitro demonstration of Tor1 being able to phosphorylate Gln3 (12) . On the other hand, the ability of Gln3 localization to exhibit a normal response to the nitrogen source provided, a hallmark of NCR-sensitive regulation, remained intact and responsive to the negative regulation of Ure2 in the absence of this Tor1 association and inability to respond to rapamycin addition. These observations argue that Tor1 associationdependent, rapamycin-elicited Gln3 regulation is a distinct and genetically separable pathway from nitrogen source-responsive, NCR-sensitive Gln3 regulation.
Additivity of TorC1-Dependent and NCR-Sensitive Regulation -Beyond genetically dissecting the contributions of Tor1-and NCR-associated Gln3 regulation, the data also demonstrate the required collaboration of the two regulatory mechanisms to achieve the overall nitrogen-responsive control of Gln3 localization. NCRmediated regulation alone in cells cultured in nitrogenreplete glutamine medium was insufficient to completely sequester Gln3 in the cytoplasm; a Tor1 associationdependent contribution was also needed. On the other hand, loss of the Tor1 contribution resulted in a nuclear shift in Gln3 localization, but again one that was far from complete. Even under the best conditions, high concentrations of rapamycin were incapable of achieving more than ~30% nuclear Gln3-Myc 13 localization with similar amounts remaining completely cytoplasmic and nuclear-cytoplasmic, respectively (Fig. 1) . Complete nuclear Gln3 localization could only be achieved when cells, devoid of the Gln3 656-666 -Tor1 association, were cultured under derepressive conditions, i.e., in nitrogenlimiting proline medium, or in an ure2. This is the first time that the combined action of Tor1-and NCRassociated participation have been demonstrated to be additively required for overall wild type regulation.
It may be mere coincidence that the Gln3-Myc 13 intracellular distribution profiles observed in mutants However, this is a lot of positive correlation to be mere coincidence. Rapamycin treatment could mimic the loss of the Tor1-Gln3 interaction, but could go no further. In other words, rapamycin effects were restricted to reversing the outcome of Tor1 association-dependent actions. To maintain proper perspective, however, it is important to point out that the data neither indicate that residues putatively phosphorylated by Tor1 are the same as those putatively dephosphorylated by rapamycin-elicited phosphatase action, nor that rapamycin treatment is preventing Tor1-dependent phosphorylation. Putative Tor1 associationdependent phosphorylation and cytoplasmic sequestration may well be a completely independent event from rapamycin-elicited phosphatase action and the partial shift of Gln3 into the nucleus.
Although previous data strongly suggested that two separate regulatory systems were responsible for regulating Gln3 localization (20) (21) (22) (23) (25) (26) (27) (28) (29) (30) (31) , they suffered from the unavoidable caveats that observed results could potentially have derived from indirect effects of the conditions employed. This caveat derived from the fact that inhibitors functioned at remote sites from the reporter protein whose localization was being influenced, Gln3-Myc 13 , and mutant studies involved molecules other than Gln3 itself. In the present work these caveats have been greatly minimized or eliminated because separation of TorC1-and NCR-associated components of Gln3 regulation derived from direct alteration of its target protein, the Gln3-Myc 13 molecule itself. With What Does Gln3 Interact? -Data in this work and the earlier study of Carvalho et al. clearly demonstrate a positive Tor1-Gln3 interaction using the standard two-hybrid interaction assay. However, this assay has the caveat of not specifying whether the physiologically significant, in vivo interaction(s) visualized are direct or indirect. One need look no further than Carvalho et al. ' s data for such a precedent. Their two-hybrid results visualized Tor1 interactions with Gln3, Ure2, Dal81, Dal82, Gat1, and Gzf3 (8) . Gln3 is known to interact with Ure2 and Dal82 (6) (7) (8) (42) (43) (44) . However, Dal81 interacts with Gln3 only in a Dal82-dependent manner (44) . Therefore, it may be premature to conclude that Gln3 binds directly to Tor1. Although in vitro Tor1 clearly mediates Gln3 phosphorylation (8) , it is worth noting that Gln3 contains 146 serine/threonine residues providing a wide in vitro selection of possible phosphorylation candidates that may or may not be physiologically significant. However, the present study provides an excellent highly defined probe to search for other molecules with which Gln3 656-666 interacts. This information, which we are attempting to acquire, may contribute to a more accurate and detailed view of the mechanism through which TorC1 regulates Gln3.
Gln3 Contains More Than One Tor1-Interacting Site and Possible Implications -The data in this work also demonstrate that, based on two-hybrid assays, Gln3 contains one or more Tor1-interacting sites beyond the one situated at Gln3 656-666 . The most compelling evidence is that Gln3 , lacking the demonstrated site at Gln3 656-666 , exhibits a positive interaction with both Tor1 and Tor1 . Further, reasoning described in the Results section provides a consistent explanation of how such a putative additional Tor1-interacting site(s) may have escaped earlier detection. If additional Tor1-interacting site(s) do, in fact, exist in Gln3, they open an important question, what is their function with respect to Gln3 regulation? Our future investigations will be directed toward locating additional putative Tor1-association site(s) in Gln3 and addressing this question.
Finally, two additional items merit emphasis: (i) the observations from which our conclusions derive would not have been possible without the ability to reliably quantify Gln3-Myc 13 localization and (ii) it is quite remarkable that systematic introduction of extensive alterations throughout the Gln3 600-655 region (25% of the residues) had no significant effect on rapamycin-influenced or NCR-sensitive regulation of Gln3 localization; all but one of the multiple substitutions failed to generate a mutant phenotype. This suggests that beyond direct or indirect interaction with Tor1, the bulk of this region either plays only a limited or minimally direct role in Gln3's regulated localization or that the role it plays tolerates significant alteration. A and B) . The experimental format was the same as in Fig. 2 except for the addition of a third growth condition, proline provided as sole nitrogen source. A and B) . The experimental format was the same as in Fig. 2 except for the addition of a third growth condition, proline provided as sole nitrogen source. Gln3 1-600 (pRR1067) and Gln3 S656D, S659D, S662D  (pRR1069) . The assays were performed as described in Methods. The transformation recipient in all cases was strain PJ69-4a. The positive control was constructed by sequentially transforming PJ69-4a with pAV3-1 and pTD1-1. The negative control was a transformant containing pASTOR1-2470 (Gal4 DNA binding domain-Tor1 fusion) and pACT2 (corresponding empty vector). pRR1065, pRR1067, and pRR1069 consisted of the Gal4 activation domain fused N-terminal of the respective Gln3 genes. Viability and the test for a two-hybrid association of the transformants was determined by streaking them on the same medium in the presence and absence of 3 mM 3'-aminotriazole (3AT). The procedures, strain, fusion vectors and control plasmids were those used by Carvalho et al. (12) . 
